rigosertib
Onconova says Baxalta ends $565 million drug development deal for rigosertib
March 8, 2016Manufacturing and Production, Research and Development Baxalta, Onconova Therapeutics, drug development, rigosertib
Onconova Therapeutics says Baxalta has terminated its $565 million agreement to jointly develop the company’s lead drug candidate rigosertib. Baxalta …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
